A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Completed · Phase 2 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).

Key facts

Study ID

NCT06267846

Run by

Neurocrine Biosciences

People needed

73

Starts

2024-03-20

Expected to finish

2025-09-11

Last updated by the study team

2026-07-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Neurocrine Clinical Site — Little Rock, Arkansas, United States
• Neurocrine Clinical Site — Rogers, Arkansas, United States
• Neurocrine Clinical Site — Lemon Grove, California, United States
• Neurocrine Clinical Site — Long Beach, California, United States
• Neurocrine Clinical Site — Hollywood, Florida, United States
• Neurocrine Clinical Site — Maitland, Florida, United States
• Neurocrine Clinical Site — Decatur, Georgia, United States
• Neurocrine Clinical Site — Savannah, Georgia, United States
• Neurocrine Clinical Site — Gaithersburg, Maryland, United States
• Neurocrine Clinical Site — Dayton, Ohio, United States
• Neurocrine Clinical Site — North Canton, Ohio, United States
• Neurocrine Clinical Site — Houston, Texas, United States
• Neurocrine Clinical Site — Richardson, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.